本文選題：抗血管內(nèi)皮生長因子 + 角膜新生血管��； 參考：《眼科新進(jìn)展》2014年07期

【摘要】：角膜新生血管可能會導(dǎo)致視力嚴(yán)重減退,主要與其阻礙光線導(dǎo)致了角膜瘢痕、引起角膜的炎癥反應(yīng)和水腫進(jìn)而損害損害視力有關(guān)。角膜的無血管狀態(tài)是一個積極主動的過程,角膜能夠維持透明性是由于血管生長因子和抗血管生長因子的精確平衡。血管內(nèi)皮生長因子(vascular endothelial growth factor,VEGF)是最重要的調(diào)控介質(zhì)之一,其上調(diào)可以誘發(fā)血管生成。而抗VEGF治療對于許多疾病有效,如年齡相關(guān)性黃斑變性、糖尿病視網(wǎng)膜病變等血管生成疾病,同樣它們對于角膜新生血管的治療也具有巨大的潛力,本文就角膜新生血管的抗VEGF治療現(xiàn)狀進(jìn)行了綜述。
[Abstract]:Corneal neovascularization may lead to severe loss of visual acuity, which is mainly related to the obstruction of light, which leads to corneal scar, inflammation and edema of cornea, and damages visual acuity. Corneal avascular state is a proactive process, and corneal transparency is due to the accurate balance of vascular growth factor and anti-vascular growth factor. Vascular endothelial growth factor (VEGF) is one of the most important regulatory mediators, and its up-regulation can induce angiogenesis. Anti- VEGF therapy is effective for many diseases, such as age-related macular degeneration, diabetic retinopathy and other angiogenic diseases, and they also have great potential for corneal neovascularization. This article reviews the current status of anti-VEGF therapy for corneal neovascularization.
【作者單位】： 哈爾濱醫(yī)科大學(xué)附屬第一醫(yī)院眼科;
【基金】：國家自然科學(xué)基金資助(編號:81201184)~~
【分類號】：R772.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前1條

1 Ebru Eren Akar;Veysi 銉ner;Cem Kü，

本文編號：1816579